Xencor, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a XNCR research report →
Companywww.xencor.com
Xencor, Inc. , a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.
- CEO
- Bassil I. Dahiyat
- IPO
- 2013
- Employees
- 250
- HQ
- Pasadena, CA, US
Price Chart
Valuation
- Market Cap
- $839.75M
- P/E
- -4.94
- P/S
- 8.63
- P/B
- 1.65
- EV/EBITDA
- -11.69
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 91.99%
- Op Margin
- -217.93%
- Net Margin
- -177.10%
- ROE
- -28.77%
- ROIC
- -30.58%
Growth & Income
- Revenue
- $125.58M · 13.65%
- Net Income
- $-91,923,000 · 60.48%
- EPS
- $-1.24 · 65.36%
- Op Income
- $-177,502,000
- FCF YoY
- 33.62%
Performance & Tape
- 52W High
- $18.69
- 52W Low
- $6.92
- 50D MA
- $12.25
- 200D MA
- $12.44
- Beta
- 0.93
- Avg Volume
- 861.58K
Get TickerSpark's AI analysis on XNCR
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 10, 26 | Cornelissen Bart Jan | sell | 3,499 |
| Mar 5, 26 | Desjarlais John R | sell | 4,118 |
| Mar 6, 26 | Desjarlais John R | sell | 2,502 |
| Mar 5, 26 | Eckert Celia | sell | 3,244 |
| Mar 6, 26 | Eckert Celia | sell | 1,767 |
| Mar 5, 26 | Cornelissen Bart Jan | sell | 2,517 |
| Mar 5, 26 | Dahiyat Bassil I | sell | 14,870 |
| Mar 6, 26 | Dahiyat Bassil I | sell | 6,606 |
| Mar 2, 26 | Desjarlais John R | other | 24,907 |
| Mar 3, 26 | Desjarlais John R | sell | 2,663 |
Our XNCR Coverage
We haven't published any research on XNCR yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate XNCR Report →